Compare Vertex Pharmaceuticals Incorporated (VRTX) vs State Street Real Estate Select Sector SPDR ETF (XLRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vertex Pharmaceuticals Incorporated vs State Street Real Estate Select Sector SPDR ETF — how do they compare? Vertex Pharmaceuticals Incorporated trades at $522.29 (market cap $134.06B), while State Street Real Estate Select Sector SPDR ETF trades at $43.42. The key difference: Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, State Street Real Estate Select Sector SPDR ETF nearer its low. Which is the better fit depends on your goals.
| VRTX | XLRE | |
|---|---|---|
Market Cap | $134.06B | — |
Sector | Health | Sector/Thematic |
52-Week High | $557.96 | $46.01 |
52-Week Low | $376.62 | $40.01 |
Enterprise Value | $128.18B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Vertex Pharmaceuticals (VRTX) trades at $528.9, down 3.15% on the day, amid a mixed technical and fundamental backdrop. The stock shows a bullish moving average signal but neutral oscillators, with key support at $522. Fundamentally, 2025 revenue reached $12.0B with a strong net income margin of 35%, though recent quarterly EPS results have been mixed. The company recently completed the acquisition of Crinetics Pharmaceuticals, signaling growth ambitions.
The outlook remains positive given analyst consensus favoring a Buy rating (84%) and a $548.78 price target, implying upside. Key opportunities include revenue growth from new drug launches, while risks involve competitive pressures and earnings volatility. The stock's current valuation at a P/E of 30.8 requires sustained execution to justify further gains.
XLRE trades at $43.9, down 0.05% with a bearish technical signal from moving averages. The ETF shows neutral oscillator readings, with RSI near oversold levels. Recent news highlights real estate's resilience amid inflation, though some analysts warn of underperformance versus AI-focused alternatives. Dividend safety remains a focus, with a future dividend scheduled for June 2026.
Outlook is mixed; real estate offers diversification and income potential, but high interest rates and sector rotation pose risks. Investors should weigh XLRE's low expense ratio and U.S. focus against macroeconomic headwinds. Sentiment is cautious, with technical weakness suggesting near-term pressure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →About State Street Real Estate Select Sector SPDR ETF
XLRE tracks the Real Estate Select Sector Index, providing exposure to S&P 500 real estate companies. It focuses on equity REITs across residential, industrial, and healthcare sub-sectors, with top holdings like Welltower, Prologis, and American Tower.
Read more on XLRE →
